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Abstract
Background: Eligibility criteria that result in the exclusion of a substantial number of patients from randomized trials
jeopardize the generalizability of treatment effect to much of the clinical population. This is important when evaluating
opioid substitution and antagonist therapies (OSATs), especially given the challenges associated with treating the
opioid-dependent population. We aimed to identify OSAT trials' eligibility criteria, quantify the percentage of the clinical
population excluded by these criteria, and determine how OSAT guidelines incorporate evidence from these trials.
Methods: We performed a systematic review to identify the eligibility criteria used across trials. We searched Medline,
EMBASE, PsycINFO, Web of Science, Cochrane Library, Cochrane Clinical Trials Registry (CTR), World Health Organization
International CTR Platform Search Portal, and the National Institutes of Health CTR databases from inception to January 1,
2014. To quantify the effect of trials' eligibility criteria on generalizability, we applied these criteria to data from an
observational study of opioid-dependent patients (n = 394). We then accessed the Canadian, American, British, and
World Health Organization (WHO) OSAT guidelines to evaluate how evidence is used in the recommendations.
Results: Among the 60 trials identified the majority (≥50 % of trials) exclude patients with psychiatric (60 %) and
physical comorbidity (51.7 %). Additionally, we found 19 trials exclude patients with current alcohol/substance-use
problems (31.7 %), and 29 (48.3 %) exclude patients taking psychotropic medications. These criteria were restrictive and
in some cases rendered 70 % of the observational sample ineligible. North American OSAT guidelines made strong
recommendations supported by evidence with poor generalizability. National Institute of Health and Care Excellence
(NICE) and WHO guidelines for opioid misuse provide a critical assessment of the literature used to inform their
recommendations.
Conclusions: Trials assessing OSATs often exclude patients with concurrent disorders. If the excluded patients respond
differently to treatment, results from these trials are likely to overestimate the true effectiveness of OSATs. North
American guidelines should consider these limitations when drafting clinical recommendations.
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Background
Opioid addiction is a chronic disorder with several risk
factors contributing to its development and treatment
course [1–3]. The global impact of opioid use is apparent
and according to the United Nations Office on Drugs and
Crime there were an estimated 26.4 to 36 million (0.03 %
global population) people engaging in illicit opioid use in
2012 [4]. Within the US alone 2.1 million people are esti-
mated to be suffering from a prescription opioid addiction
[5]. The cost of opioid addiction to both patients and soci-
ety is high, with estimates in the range of 55.7 billion US
dollars [6]. A recent investigation from the RAND pro-
vides assessments of the costs of opioid addiction and esti-
mate a range from €2,627 to €60,665 per person, per year.
These estimates are comprised of data from American,
Australian and Canadian populations and quote the most
generalizable estimates encompassing the highest scope of
costs (health care, lost worker productivity) at €21,904 per
person per year [7].
Despite its high prevalence and global impact, [8] there
remain few medication-assisted treatments for opioid ad-
diction. The treatments are known collectively as opioid
substitution and antagonist therapies (OSATs) and include
both opioid agonist and antagonist treatments. Metha-
done, buprenorphine, buprenorphine-naloxone and nal-
trexone, [9] are among the regularly used treatments for
addiction patients, with methadone remaining the most
commonly prescribed [9]. Patients with opioid depend-
ence are among the hardest to manage and retain in treat-
ment [10, 11]. Their transient lifestyle, extensive social
issues, and physical comorbidities contribute to the diffi-
culties of treatment. Less than 15 % of methadone patients
successfully finish their treatment as intended, [10, 11]
and those who leave treatment have high susceptibility for
human immunodeficiency virus (HIV), relapse, and death
[10, 11]. When faced with the responsibility of treating
such complex and vulnerable populations we are expected
to trust the recommendations put forward in the clinical
guidelines.
Guidelines rely heavily on the evidence from stringently
designed trials and meta-analyses to inform their recom-
mendations [12–15]. Strict eligibility criteria can limit the
generalizability of clinical research and leave clinicians
guessing as to the effectiveness of interventions in many
of their patients [16]. For instance, trials on treatments for
opioid dependence commonly exclude patients with psy-
chiatric comorbidities [17–25] in an effort to reduce non-
compliance and determine whether a treatment works
under optimal conditions. Such selective exclusion of
difficult-to-treat patients may inflate the benefits we ex-
pect from our treatments. Patients with opioid depend-
ence are known for having comorbid physical and
psychiatric disorders [26–31] and the presence of such
disorders can adversely affect their outcomes [32–34]. For
instance, depressed people receiving opioid substitution
therapy (OST) are more likely to consume illicit sub-
stances compared to counterparts who do not suffer from
depression [32]. Since the prevalence of depression among
opioid-dependent patients is high, [31] their exclusion
from OSAT trials may bias the results and create inflated
estimates of treatment effect. The complexities associated
with managing opioid-dependent patients demand the
need for thorough clinical guidelines. Accordingly, there is
an enormous responsibility to ensure guidelines: (1) rely
on the up-to-date evidence with high internal validity;
(2) provide information on the populations that may re-
spond differently to treatment and; (3) are transparent
about the limitations of the evidence and their ability to
provide strong recommendations. Assessment of the
generalizability of OSAT trials to real practice and identifi-
cation of important factors limiting generalizability are
key steps in translating the evidence generated by these
trials into practice.
While the impact of strict inclusion criteria on the
generalizability of trial evidence has been previously evalu-
ated in addiction research, [35–40] these studies are
focused on alcohol- and cannabis-dependent populations,
where the inclusion criteria and clinical implications may
vary greatly from that of opioid-dependent populations.
To our knowledge no study has investigated the eligibility
criteria of OSAT trials. We set out to: (1) identify OSAT
trials’ eligibility criteria and other design characteristics;
(2) quantify the proportion of the clinical population ex-
cluded by these criteria and; (3) determine how the most
recent American, Canadian, British, and World Health
Organization (WHO) OSAT treatment guidelines incorp-
orate evidence from these trials.
Methods
Review
The protocol for this systematic review has been previ-
ously registered (Prospero ID: CRD42013006507) and
described elsewhere [41]. The protocol for this review
details a larger network meta-analysis currently in pro-
gress [41]. Briefly, we performed a systematic review to
identify all randomized controlled trials (RCTs) evaluating
the effect of a substitute opioid therapy for improving
treatment response in opioid-dependent patients. We
searched Medline, Excerpta Medica DataBase (EMBASE),
PsycINFO, Web of Science, Cochrane Library, Cochrane
Clinical Trials Registry (CTR), WHO International CTR
Platform Search Portal, and the National Institutes of
Health (NIH) CTR databases from inception to January 1,
2014. We asked each primary investigator listed on the
NIH Clinical Trial Registry from studies deemed eligible
from the title screen of the NIH trial library to submit a
list of publications resulting from their trial. We also hand
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searched all Cochrane reviews evaluating the effectiveness
of any OSAT to identify additional studies.
We included only studies evaluating the effectiveness of
any opioid agonist or antagonist substitution therapy in
patients with opioid addiction. Studies evaluating the
effect of OSAT on specialized populations including co-
caine- or alcohol-dependent patients were excluded. We
will highlight again that the trials used for this review were
identified as part of a larger network meta-analysis aiming
to evaluate the impact of different OSTs in the general
opioid addiction patient populations. Studies included
were required to investigate the efficacy of an OSAT using
one or more of the outcomes of interest: illicit substance
use, treatment attrition, criminal behavior, mortality, phys-
ical and psychological well-being as well as adverse events.
We placed no age or language restrictions on our search.
However, we did require all studies be primary investiga-
tions with direct comparison groups (separated by a treat-
ment or placebo). No studies evaluating a single treatment
were included (e.g., cohort, cross-sectional studies). We
extracted information on the stated trial objectives, eligi-
bility criteria, and study design. All trials eligible for inclu-
sion were subject to risk of bias assessment using the
Cochrane Risk of Bias Tool [42]. We used the kappa stat-
istic to assess inter-rater agreement, [43], which is prefera-
ble to percent agreement calculations since it takes into
account any agreement occurring by chance. Kappa values
range from 0 to 1, with values closer to 1 indicating a
higher level of agreement [43]. Disagreements during the
screening and abstraction process were resolved by con-
sensus. This review adheres to the reporting standards set
out by the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) guidelines [44].
We then applied trials’ reported eligibility criteria to a
sample of 394 opioid-dependent patients participating in
the GENetics of Opioid Addiction (GENOA) study, a
collaboration between McMaster University and the
Canadian Addiction Treatment Centres (CATC).
GENetics of Opioid Addiction (GENOA) prospective cohort
study design
GENOA is an ongoing observational study of the genetic,
biological, and social determinants of treatment response
for opioid-dependent patients. The GENOA population is
made up of opioid addiction patients actively receiving
methadone treatment at a CATC facility. The CATC
(formerly known as the Ontario Addiction Treatment
Centre) are the largest network of methadone addiction
treatment facilities in North America – with over 12,000
patients and 57 clinical sites across Canada. Over the past
20 years CATC has treated over 50,000 patients.
Although changes were made to enhance the study’s
feasibility and internal validity, the findings and details of
methodology employed during the GENOA pilot phase
are described elsewhere [45]. Changes made following the
pilot phase include: relaxing eligibility criteria, utilizing a
prospective cohort design with a follow-up duration of
12 months, and integrating the use of validated tools such
as the Brief Pain Inventory (BPI) to assess pain [46], the
Mini International Neuropsychiatric Interview version 6.0
(MINI) [47] to assess for psychiatric comorbidities, and
the Maudsley Addiction Profile (MAP) instrument to
assess addiction severity across personal, physical, and so-
cial functioning domains [48]. To be eligible for GENOA
participants were required to be at least 18 years old and
able to provide informed consent.
GENOA participants are opioid addiction patients re-
ceiving methadone for the treatment of opioid depend-
ence. GENOA participants are recruited directly from
CATC methadone treatment facilities. Participants pro-
vide an initial blood sample as well as addiction severity,
pain, and psychiatric assessment at the baseline interview.
Participants also provide urine samples to assess for sub-
stance use. Over the course of their 12-month follow-up
GENOA participants are asked to partake in additional
addiction severity assessments using the MAP [48] as well
as urine toxicology screening at 3-month intervals.
The CATC is made of up 57 clinical facilitates adminis-
tering pharmacological therapies for opioid addiction
including methadone and buprenorphine. The CATC pro-
gram offers clinical services including clinical interview to
assess opioid dependence according to Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM IV) criteria, medical examination and laboratory
tests, where appropriate, supervised urine testing and ini-
tiation of treatment plan. CATC comprises the largest net-
work of addiction treatment facilitates in North America
treating over one-third of Ontario’s opioid addiction
population. From rural northern Ontario to populous
downtown Toronto there is substantial variability in the
geographic and economic populations CATC serves, offer-
ing a healthy case mix of patients being recruited into the
GENOA study. The social, economic, and geographical
discordance between CATC sites (both in general and
those included in GENOA) increases our confidence in
the generalizability of this sample.
We searched www.guidelines.gov for the most recent
American and Canadian guidelines with the terms
“opioid dependence,” “opioid addiction,” and “opioid
substitution treatment.” These search terms were used
individually for three separate searches. We also used the
National Institute for Health and Care Excellence (NICE)
to identify the most recently published clinical guidelines
for substitute opioid therapies used by the National Health
Service in the UK. WHO guidelines were accessed dir-
ectly from http://whqlibdoc.who.int/publications/2009/
9789241547543_eng.pdf. We extracted information on
recommendations made by each guideline, the grade
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assigned to that recommendation, evidence cited by the
guideline, any cautions regarding clinical subgroup ef-
fects, and whether the guideline discussed the popula-
tions in which the interventions were tested.
The guidelines were also subject to additional evaluation
using specific domains from the Appraisal of Guidelines
for Research and Evaluation II (AGREE) Instrument. The
AGREE II instrument is a validated and reliable tool used
to assess the quality of clinical guidelines [49, 50]. The
instrument comprises 23 items organized into six quality
domains: scope and purpose; stakeholder involvement;
rigor of development; clarity of presentation; applicability;
and editorial independence [49]. We chose to assess the
guidelines using the AGREE II rigor of development and
applicability domains since our guideline-specific objective
was to determine how the guidelines incorporate evidence
into the development and dissemination of clinical recom-
mendations. Two independent reviewers assessed the
guidelines according to the detailed instructions provided
for the AGREE II.
Data synthesis and statistical analysis
We summarized categorical variables as proportions and
percentages and continuous variables as means with
standard deviations. All analyses were performed using
Stata 13.1 [51].
Results
Findings from systematic review of common eligibility
criteria used across OSAT trials
Figure 1 outlines the study screening process. We
screened 5303 unique articles after removing 774 dupli-
cates with good agreement between reviewers (kappa,
0.71 (standard error [SE] 0.02), 0.85 (SE 0.03), and
0.73 (SE 0.06) for the title, abstract, and full-text
screening respectively). The title search was performed
in January 2014. A list of the 60 trials included in this re-
view is summarized in Additional file 1. During full-text
review 77 articles were excluded, whereby 10 articles iden-
tified during the hand-search of Cochrane reviews were
duplicates, seven studies did not review an outcome of
interest, 36 studies were not randomized trials, one study
showed contamination of intervention, six studies used
data-linkage/retrospective data design, one study stratified
all analyses by sex, and six studies were performed in a
specialized population (e.g., cocaine-dependent patients).
Trials identified for inclusion evaluated the effect of
methadone, buprenorphine, heroin, naltrexone (oral and
implant), combination buprenorphine and naloxone, levo-
α-acetylmethadol (LAAM), and morphine. Forty-five per-
cent of trials reported establishing drug efficacy as their
primary objective, 20 % reported drug effectiveness as the
primary trial aim, and 26 % failed to explicitly state an ob-
jective. Table 1 summarizes the eligibility criteria reported
across trials, as well as the percentage of opioid-
dependent patients from the GENOA sample (n = 394)
who satisfy each criterion. Trials often included adult pa-
tients (100 %, all 60 trials), meeting the DSM-IV or Inter-
national Classification of Disease (ICD) criteria for opioid
dependence (38.3 %, 23 trials), and exclude patients with
psychiatric (60 %, 36 trials) or chronic physical comorbidi-
ties (51.7 %, 31 trials). The definitions, measurements, as
well as cut-offs used to assess psychiatric and physical
functioning varied substantially across trials. While some
studies provide a detailed description of conditions that
would deem patients ineligible for inclusion, other studies
lacked such sufficient detail thus jeopardizing the repro-
ducibility of their trial. For instance, one of the higher
quality studies published in the Lancet by Schottenfeld
et al. (2008) provides a list of conditions they deemed
problematic for inclusion into the trial without once
discussing how such conditions were measured, “Patients
were ineligible if they were dependent on alcohol, benzodi-
azepines, or sedatives; had concentrations of liver enzymes
(alkaline phosphatase or alanine transaminase) greater
than three times the upper limit of normal; were danger-
ous to themselves or others; were psychotic or had major
depression; or had life-threatening medical problems,”
[19]. This type of description was not uncommon, whereby
the majority of studies lacked any explanation of the
methods used to assess for different physical conditions or
demographic characteristics.
The most restrictive criteria were the exclusion of pa-
tients with psychiatric comorbidities or those using alco-
hol and other substances, which alone renders 74.4 % of
the GENOA participants ineligible for inclusion. While
not as commonly reported (<50 % of trials), the applica-
tion of other restrictive criteria such as the exclusion of
patients who take psychotropic medications and the
requirement for intravenous drug use behavior would
render 50 and 93 % of the sample ineligible for inclusion
respectively.
The use of evidence in clinical practice guidelines
We identified three North American guidelines for
the treatment of opioid dependence using the
www.guidelines.gov database [12–14]. We identified
the UK clinical practice guidelines for opioid maintenance
therapy using the NICE database [52]. We also evaluated
the WHO 2009 international guidelines for managing
opioid-dependent patients [53]. Tables 2 and 3 summarize
the recommendations made by each guideline, the grade
assigned to that recommendation, evidence cited by the
guideline, any cautions regarding clinical subgroup effects,
the number of GENOA participants excluded by the com-
bined eligibility criteria reported in the trials cited in the
guideline, and whether the guideline discussed the popula-
tions in which the interventions were tested.
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The most recent clinical practice guidelines for manage-
ment of substance use disorders from the US Department
of Defense and Department of Veteran Affairs (2009) uses
evidence from both trials and observational studies to
inform recommendations for methadone and buprenor-
phine opioid substitution treatment [13]. The recommen-
dations made within the US guidelines were based on
evidence from trials excluding patients with psychiatric
disorders, [54, 55] concurrent alcohol or poly-substance
use, [54–56] and the patients prescribed psychotropic
medications [55, 56]. The College of Physicians and
Surgeons of Ontario published the most recent metha-
done guidelines, utilizing a systematic search across five
databases and the grey literature [12]. The guideline com-
mittee found only four studies to address the issue of
methadone effectiveness among prescription opioid users,
with large weight placed on a retrospective observational
study [57] and a systematic review lacking a risk of bias
assessment [58]. Similar to the methadone maintenance
guidelines, the Canadian guidelines for buprenorphine rely
on evidence from trials and systematic reviews of studies
excluding patients on psychotropic medications, and pa-
tients with serious physical comorbidities as well as con-
current substance/alcohol dependence [14]. The Canadian
guidelines did not provide a description of how they eval-
uated the individual studies used to support their recom-
mendations [12, 14]. There is no explicit discussion of the
risk of bias assessment conducted on the supporting body
of evidence [12, 14]. When applying the criteria reported
by the trials cited in each guideline we find the Canadian
buprenorphine/naloxone guideline [14] are basing their
recommendations on the most restrictive evidence,
whereby only seven participants from the GENOA sample
meet the combined eligibility requirements.
Contrary to the practices used by North American
guideline panels, the NICE and WHO clinical practice
Fig. 1 Systematic review study selection flow diagram
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guidelines for opioid misuse provide an appraisal of the
evidence used to inform the guidance and suggest the im-
portance of managing comorbid disorders with the use of
psychosocial interventions during maintenance therapy
or before using an OSAT to treat opioid dependence
[52, 53]. WHO guidelines provide explicit recommenda-
tions for managing participants with comorbid disorders
(poly-substance use, pregnancy, psychiatric disorders) as
well as transparency with respect to the evidence used to
inform recommendations [53]. NICE guidelines provide
disclaimers for the knowledge users about the populations
the interventions were tested in, and the overall limita-
tions for using the evidence to guide recommendations in
specific subpopulations [52]. WHO guidelines go so far as
suggesting comorbid disorders be addressed by the same
consultant, a method used for increasing uptake and ad-
herence to OSAT [53]. While WHO guidelines provided a
section detailing recommendations for important subpop-
ulations, they did not discuss any of the important issues
of generalizability [53]. Moreover, WHO guidelines went
so far as suggesting there was no uncertainty as to the dir-
ectness of the evidence in their evidence profile for the
questions, “Is methadone effective for the treatment of
opioid dependence?” despite the concerning stringent in-
clusion criteria applied across trials [53]. In fact, the only
criticisms WHO raised with respect to the generalizability
of the evidence were in the case of studies performed on
in-patient populations [53].
Table 4 summarizes the application of the AGREE II
instrument to the guidelines. A domain-specific score is
provided for each guideline in addition to the individual
item scores. The UK and WHO guidelines ranked highest
for the rigor of development and applicability domains
(Table 4). Within this domain, UK and WHO guidelines
Table 1 Summary of eligibility criteria reported across trials
Trial eligibility criteria Number of trials reporting
criteria k (%), (k = 60)
Number of GENOA participants
meeting criteria n (%), (n = 394)
Inclusion criteria
Age ≥18 30 (50.0) 394 (100.0)
DSM-IV or ICD criteria for opioid dependence 23 (38.3) 394 (100.0)
Requirement of previous MMT Treatments or currently receiving methadone 18 (30.0) 394 (100.0)
Provision of positive opioid urine test 18 (30.0) /
Daily injecting drug use patterns or intravenous drug use behavior 11(18.3) 28 (7.1)
Addiction Severity Score (i.e., >8 on MAP or >12 on ASI) 5 (8.3) 168 (42.6)
Explicit willingness to follow methadone treatment regime 4 (6.7) 394 (100.0)
Educational requirements (high school diploma) 4 (6.7) 352 (89.3)
Abstinence from alcohol and other substances for 1 week prior to study entry 3 (5.0) /
Reported criminal behavior in last 6 months 1 (1.6) 24 (6.1)
Exclusion criteria
Presence of psychiatric comorbidity 36 (60) 293 (74.4)
Presence of chronic physical comorbidity 31 (51.7) 225 (57.1)
Presence of acute physical problems 30 (50.0) 106 (26.9)
Presence of psychotropic or neuroleptic medication 29 (48.3) 193 (50.0)
Pregnancy 27 (45.0) /
Concurrent alcohol or substance abuse problems 19 (31.7) 293 (74.4)
Abnormal liver enzymes 9 (15.0) /
Presence of HIV 1 (1.7) 3 (0.76)
/ Indicates this information is not available in the GENOA sample
k indicates trials
Criminal behavior among GENOA participants included: drug trafficking, theft, prostitution, fraud
Psychiatric comorbidity determined using MINI psychiatric evaluation on all GENOA participants (n = 394)
Substance use among GENOA participants included: heroin, benzodiazepine, cannabis, cocaine, crack cocaine, and alcohol
Chronic physical comorbidity was measured in the GENOA sample as a composite outcome of one or more of: HIV, chronic pain, liver disease, hepatitis, diabetes,
epilepsy, or other
Acute physical problems determined in GENOA sample using MAP physical symptoms scores (participants reporting <20 were considered to have no acute
physical health problems)
GENOA Genetics of Opioid Addiction, DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, ICD International Classification of Disease, MMT
methadone maintenance treatment, MAP Maudsley Addiction Profile, ASI Addiction Severity Index, HIV human immunodeficiency virus, MINI The Mini International
Neuropsychiatric Interview
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Table 2 Guidelines available for evaluation of the appropriateness of opioid agonist and antagonist treatments for patients with opioid dependence
Title of guideline Country Year Intervention(s) assessed Outcome Clinical trial design
characteristics in
supporting evidence
Use of observational studies Meta-analyses included






USA 2009 Methadone and
buprenorphine
Decrease in opioid use
(relapse prevention)
Explanatory by design
with strict eligibility criteria








USA 2009 Methadone and
buprenorphine
Retention in treatment Explanatory by design
with strict eligibility criteria
No No discussion of poor
methodological quality







USA 2009 Naltrexone Decrease in opioid use
(relapse prevention)
and retention
Explanatory trials by design
with strict eligibility criteria
used within meta-analysis
No Meta-analyses provided






Canada 2011 Buprenorphine/naloxone Decrease in opioid use
(relapse prevention)
and retention
Explanatory trials by design











Canada 2011 Methadone maintenance
treatment
Decrease in opioid use
(relapse prevention)
Explanatory trials by design
with strict eligibility criteria
used within meta-analysis
and cited trials
Yes No discussion of methodology








UK 2007 Methadone and
buprenorphine
Decrease in opioid use
(relapse prevention)
and retention
Explanatory trials by design
with strict eligibility criteria
used within meta-analysis
and cited trials
Yes, provide evidence from
systematic reviews of trials
and non-randomized studies











Decrease in opioid use,
treatment retention
Explanatory trials by design
with strict eligibility criteria
used within meta-analysis
and cited trials
Yes, provide evidence from
systematic reviews of trials
and non-randomized studies











Table 3 International guideline assessment of the evidence for substitute opioid therapy in treatment of opioid dependence (assessment of recommendations based on effect
reported in literature)
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routine provision
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patient’s last treatment
at the clinic
Not graded Not reported There are guideline
suggestions provided
but no “rank” of
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Table 3 International guideline assessment of the evidence for substitute opioid therapy in treatment of opioid dependence (assessment of recommendations based on effect
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Good evidence refers to high-grade evidence (with at least one properly designed randomized trial) directly linked to health outcome
Poor to fair refers to high-grade evidence (with at least one properly designed randomized trial) linked to intermediate outcome or moderate-grade evidence (evidence obtained from well-designed cohort or case–control
analytic studies, evidence obtained from multiple time series studies; dramatic results in uncontrolled experiments) directly linked to health outcome and/or refers to opinions of respected authorities; descriptive studies and
case reports; reports of expert committees of evidence or no linkage of evidence to health outcome
DSM-IV Diagnostic and Statistical Manual of Mental Disorders










scored a 93, and 95 respectively. Additionally each guide-
line (UK and WHO) consistently ranked 6 and 7 (strongly
agree). This indicates the European guidelines use system-
atic methods to identify the supporting evidence in
addition to being transparent about guideline develop-
ment and the limitations of the evidence used to support
their recommendations. The North American guidelines
ranked considerably lower at 50, 44, and 27 respectively
for the United States, Canadian buprenorphine, and
Canadian methadone guidelines. WHO and UK guidelines
again ranked highest within the applicability domain
(scores 93, 86 respectively). The Canadian buprenorphine
guidelines did not follow far behind with a domain score
of 67. The Canadian buprenorphine guidelines spent
considerable time describing the need to move buprenor-
phine on the all provincial drug benefit plans to ensure ac-
cess for all opioid-dependent patients [14]. The American
and Canadian methadone guidelines fell further behind
with domain scores of 25 and 29 respectively. Table 4 pro-
vides a summary of the individual scores, allowing us to
evaluate where guidelines performed weakest according to
AGREE II.
Discussion
This study provides an overview of the limitations of OSAT
literature, using multiple resources including results from a
well-designed systematic review, [41] and an application of
the findings within a clinical sample of opioid-dependent
Table 4 Application of the rigor of development and applicability AGREE II domains to international guidelines for substitute opioid
therapy in treatment of opioid dependence


















Domain III: rigor of development
Systematic methods were used to search
for evidence
2 3 5 7 7
The criteria for selecting the evidence are
clearly described
2 2 4 7 6
The strengths and limitations of the body
of evidence are clearly described
1 2 2 6 7
The methods for formulating the
recommendations are clearly described
3 2 4 6 7
The health benefits, side effects, and risks
have been considered in formulating the
recommendations
5 5 6 7 6
There is an explicit link between the
recommendations and the supporting
evidence
4 3 4 6 7
The guideline has been externally
reviewed by experts prior to its
publication
2 7 1 7 7
A procedure for updating the guideline is
provided
2 5 6 6 6
Domain score 27 44 50 93 95
Domain V: applicability
The guideline describes facilitators and
barriers to its application
4 4 2 6 7
The guideline provides advice and/or
tools on how the recommendations can
be put into practice
3 6 3 6 6
The potential resource implications of
applying the recommendations have
been considered
2 6 3 7 7
The guideline presents monitoring and/or
auditing criteria
2 4 2 5 6
Domain score 29 67 25 86 93
AGREE Appraisal of Guidelines for Research and Evaluation, NICE National Institute for Health and Care Excellence
Dennis et al. Trials  (2015) 16:475 Page 11 of 18
patients [45]. This study also provides a systematic assess-
ment of the guidelines, highlighting the important limita-
tions we can work to improve for the future.
Results from this systematic review suggest trials most
often include adult patients meeting the DSM-IV/ICD cri-
teria for opioid dependence with intravenous drug use be-
havior and a past history of methadone treatment. Trials
most often exclude participants having a psychiatric or
chronic physical comorbidity, current alcohol or substance
use problem, as well as those taking psychotropic medica-
tions. When applying these criteria to a clinical sample of
methadone patients we found them to be largely restrict-
ive, and in some cases render 70 % of the GENOA sample
ineligible. Criteria such as the exclusion of participants
with psychiatric or physical comorbidity, concurrent
alcohol/substance use problems, as well as those using
psychotropic medication appeared to have the largest cost
to recruitment, where more than 50 % of the GENOA
sample would be lost by the application of such criteria.
The majority of international clinical practice guidelines
rely on out-of-date systematic review evidence to inform
guidance development as well as making strong recom-
mendations based on many of the trials with strict eligibil-
ity that we assessed in our review. Assessment of both
Canadian and American guidelines revealed concerning
practices, where both panels provide numerous trials as
evidence supporting recommendations for different opioid
substitution treatments without once discussing the im-
pact of trial eligibility criteria [12, 13]. The guidelines nei-
ther acknowledge the restrictive design of the trials or the
generalizability of the evidence [12–14]. The guidelines go
so far as to rank the quality of the evidence as good, des-
pite the concerning limitations we have raised for each of
the cited studies [12, 13]. These issues are highlighted
further when we applied the combined eligibility criteria
reported by trials cited in the guidelines to the GENOA
sample, whereby the highest number of GENOA partici-
pants these studies could have been generalized to would
include 20 people out of 394.
Additionally, when applying the AGREE II rigor of de-
velopment and applicability domains we found the North
American guidelines performed considerably worse in
using systematic search methods to identify research, and
reporting the limitations as well as generalizability of the
evidence. These practices were contrary to the transpar-
ency of reporting found in the WHO and UK guidelines.
Use of the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) of guidelines cri-
teria is likely impacting the stark quality differences be-
tween North American and European guidelines [59].
European guidelines provide transparent appraisal of the
evidence used to inform recommendations and even go so
far as cautioning the application of the evidence in psychi-
atric or criminal populations [52]. These findings suggest
the need for North American guideline committees to
evaluate and impose the critical evidence synthesis ap-
proaches utilized by the WHO and NICE.
Understanding the evidence and the need for change
The use of restrictive eligibility criteria is often set by in-
vestigators to ensure the safety for recruited patients to
the new intervention being tested and to maximize the
chances of observing a treatment effect under optimal
conditions. Prior to phase III trials, interventions have
never been tested in randomized comparison design.
Entry into phase III efficacy trials is governed by restrictive
eligibility criteria and conduct is often controlled by rigid
protocols. This may explain why many of the trials identi-
fied for this review adhered to an explanatory design.
Testing the effect of interventions on highly specific
groups may be associated with unintended harm to pa-
tients once the intervention is released for use in the gen-
eral population. Our results indicate the majority of
opioid substitution therapy trials exclude participants with
major psychiatric disorders. This exclusion criterion is in
no way novel, in fact many trials exclude patients with
psychiatric comorbidities. What is concerning is the lack
of understanding over what may happen to these popula-
tions once the drug is released for wider use. For example,
varenicline was tested in a randomized double-blind pla-
cebo controlled trial to assess its efficacy for reducing
smoking [60]. This trial excluded participants with a
history of psychiatric comorbidity including: major de-
pression requiring treatment within the past year, panic
disorder, psychosis, bipolar disorder, or anorexia nervosa
or bulimia [60]. Upon Food and Drug Administration
(FDA) approval for use in the general population, many
patients began to present with psychiatric symptoms in-
cluding erratic behavior and suicide attempt [61]. Many
now criticize the pharmaceutical company for marketing
the use of this drug in the general population before
knowing the real effect of the intervention in participants
with psychiatric comorbidities, especially since smoking is
prevalent among patients with psychiatric disorders.
These side effects would have been better noticed had the
proper implementation trials taken place, or had the inter-
vention been tested in a more representative sample.
Future directions
There are important reasons why patients with certain co-
morbidities (physical, psychiatric) are excluded from trials.
Efficacy trials seek to determine whether the intervention
actually works under the appropriate conditions. When
the objective of a trial is to determine the effect and safety
of an intervention an appropriate design would be to test
the intervention under optimal conditions. Patients with
psychiatric comorbidities, especially those with addictive
disorders are known to have difficulty complying with
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interventions, [62] and the inclusion of these participants
can dilute the treatment effects we observe in trials. This
trend suggests the results from stringently designed trials
reporting small treatment effects are unlikely to withstand
the inclusion of non-compliant patients. For instance,
results from one trial show a significant hazard ratio (HR)
for the comparison of buprenorphine to naltrexone for
improvement of patient retention (HR: 1.56; 95 % confi-
dence interval [CI]: 1.01, 2.41) [19]. This trial’s findings
are fragile and unlikely to sustain a small number of
changes to the reported events across treatment arms,
which would be the likely outcome had the trial been per-
formed in a more pragmatic patient population [19].
It is important we address the need for inclusion of
non-compliant participants in trials. Recognizing that
patients already have challenges complying with the strict
methadone treatment regimes [62], this issue is further
complicated for trials recruiting addiction patients be-
cause of the high prevalence of concurrent psychiatric co-
morbidities [45], which are known to impact intervention
adherence [62]. There have been suggestions for improv-
ing compliance among patients with psychiatric disorders;
one emphasized in the literature is the use of telephone
and electronic reminders [62], which has been demon-
strated to improve compliance in non-psychiatric patients
[63, 64]. Other ways to improve patient compliance with
addiction treatment include focusing on adherence
through educational sessions with family health teams,
consistent symptom measurement, and appropriate treat-
ment tailoring [65]. Instead of excluding these participants
from trials and limiting the generalizability as well as un-
derstanding of the treatment within a population represent-
ing a good portion of addiction patients, we encourage
trialists to design studies with features that help increase
patient compliance so to ensure an understanding of in-
terventions effectiveness in the clinical population.
We recognize there are also other important reasons
guiding the design of strict protocols, for instance the ex-
clusion of pregnant women or patients with acute physical
conditions may be a protective measure in efficacy trials
where drug safety is still being determined. However, the
real problem arises when we rely exclusively on evidence
from these trials before we can determine the effectiveness
in a “real world” sample of different types of patients (e.g.,
patients with comorbidities or on psychotropic medica-
tions). The limitations of the strictly designed protocols
that govern efficacy and safety of trials have been largely
addressed by the introduction of implementation trials,
which are investigations whose primary aim is to test
treatments using flexible protocols for participant selec-
tion and treatment administration. These trials often have
lax eligibility criteria with the aim of including the partici-
pant we will find in the clinical practice population.
However, these trials are not common in the field of
addiction medicine, restricting us to the use of stringent
efficacy trials to inform clinical guideline development.
Uptake in the planning and commitment to implemen-
tation or “effectiveness” research will likely stem from an
increase in discussion and acceptance of the need for
pragmatic trial designs. The goal in implementation trial
design should be to maximize the safety of participants
included in the trial while also balancing the applicability
of the findings. Pragmatic trials – sometimes called imple-
mentation trials – are evaluated on a continuum and
should not be characterized by a specific set of criteria
[66]. We recommend future trials in addiction medicine
need not abandon all “explanatory,” or more stringent
designs but instead work to evaluate the intervention in a
wide range of participants as a secondary objective. Imple-
mentation trials should aim to include those participants
with psychiatric comorbidities, poly-substance use disor-
ders, and chronic physical conditions. Provided there are
enough patients within each subgroup, researchers may be
able to evaluate the mediating impact of each comorbidity
and with confidence determine the true impact of physical
or psychiatric abnormalities within addiction patients.
Limitations
Reliance on a treatment sample of methadone patients
may potentially impact the generalizability of this study.
Using the GENOA sample of participants provides a
unique opportunity to demonstrate the restrictive impact
of eligibility criteria reported in the addiction literature.
However, demonstrating such an effect requires the use of
a generalizable sample of addiction patients. Participants
recruited from the CATC comprise a treatment sample,
which may in fact have higher levels of comorbidities
(both physical and/or psychiatric) than patients earlier on
in the cycles of addiction. By the time patients are receiv-
ing pharmacological therapy for opioid dependence they
are often at a later stage in their addiction course, placing
them at higher risk for exposure to HIV, hepatitis, infec-
tious disease, opioid-induced hyperalgesia, and poor so-
cial/economic living conditions. In addition, patients may
only seek treatment once their physical, psychiatric, or so-
cial functioning is seriously impeded. In fact, the GENOA
sample may lack the population of patients experiencing
the range of problems which often coerce or force individ-
uals into treatment altogether. However, we must also
acknowledge that addiction is a complex disorder, often
accompanied by serious physical and psychiatric comor-
bidities. Incident misuse of opioids is known to result
from serious physical comorbidities such as pain [67] and
from suffering experienced as a consequence of anxiety or
depression [68]. Recognizing there may be discordance
between prevalent users currently seeking treatment and
more “incident” cases, we maintain the clinical profile of
incident users also reflects a high degree of mental and
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physical abnormality. We emphasize the CATC popula-
tion of patients may be a prevalent sample of addiction
treatment-seeking patients, and that the results from these
trials are generated to inform the treatment of such popu-
lations, and as such it is still important we demonstrate
the large effect these criteria may have on weakening the
directness of the evidence.
We acknowledge that observational studies are subject
to selection bias, whereby patients agreeing to participate
in the study may reflect a different population. To evaluate
such bias we have elected to compare the demographic
and clinical characteristics of participants in the GENOA
study to a sample of CATC patients from four economic
and geographically diverse clinics. This sample of CATC
patients includes population data from four clinics and in-
cludes demographic and clinical characteristics data from
all patients actively receiving treatment from these sites.
Please refer to Table 5.
The GENOA sample was largely representative of the
general CATC population, whereby the mean age, mean
methadone dose (mg/day), prevalence of HIV, as well as
marital status was not statistically significantly different
between samples. There were, however, some differences,
whereby the general CATC patients were shown to have a
higher prevalence of hepatitis C and on average a shorter
treatment duration. Additionally, the general CATC sam-
ple was made up of a higher proportion of men than
found in the GENOA population. These results do suggest
that the GENOA participants are made up of patients with
longer treatment duration and as such these patients are
likely susceptible to having a higher number of physical or
psychiatric comorbidities. However, these results also sug-
gest the CATC population has a higher level of hepatitis
than our sample, which may also suggest the GENOA
study may be subject to a “healthy volunteer bias,”
whereby sicker patients are less likely to engage in the
study. Inadvertently, this would bias our own results
toward the null and overall suggests more participants in
the “general” active treatment population would be ex-
cluded that we are purporting.
In Canada buprenorphine is not covered by the provin-
cial drug insurance plans, and as such these patients
reflect either (1) an employed population with benefits
covering therapy, or (2) those patients who can afford out-
of-pocket coverage. In light of the administrative differ-
ences between methadone and buprenorphine coverage,
we chose to include only the sample of methadone pa-
tients in the GENOA investigation, which could reflect a
more marginalized population of drug treatment-seeking
patients and is a potential limitation to the generalizability
of the GENOA sample.
Information regarding criminal offences, sexual behav-
ior, and domestic conflict were collected by self-report
from patients agreeing to participate and thus likely
underestimated due to social desirability bias. We ac-
knowledge social desirability bias may impact the esti-
mates for some of the demographic data collected in this
study. However, we maintain important variables, such as
psychiatric comorbidity, were ascertained using a validated
questionnaire, the MINI. In addition, physical comorbidity
(diabetes, chronic pain) was evaluated using self-report
and confirmed via information logged by attending physi-
cians in the patients’ electronic medical record. Urinalysis
was performed to ascertain poly-substance use. We aimed
to include as many objective measurements as possible,
and when unavailable we relied on safeguards such as
electronic medical record confirmation.
Additionally, we may find that the definitions, measure-
ments, and cut-offs (if relying on measurement tools) used
to assess for physical and psychiatric functioning across
clinical trials may be quite different than those used in the
GENOA study. Thus, there is potential that the exclusion
criteria reported across trials and later applied to the
GENOA sample are being misused. Psychiatric comorbidity
Table 5 Comparison of the demographic and clinical characteristics of GENOA participants to the general population of CATC
patients
Demographic and clinical characteristics CATC population level data, N = 1354 GENOA sample, n = 394 Statistical significance observed
testing differences between groups
Mean age (SD) 38.4 (10.7) 38.5 (10.9) 0.87
Sex (percentage male) 66.9 53.3 p <0.05
Mean duration on MMT in years (SD) 2.1 (1.2) 4.3 (4) p <0.05
Mean methadone dose in mg per day (SD) 81.9 (53.5) 78.1 (41.2) 0.19
Hepatitis C positive % 29.9 22.3 p <0.05
HIV positive % 0.3 0.8 0.19
Marital status (% single, divorced) 64.8 68.2 0.19
Two-sample t test used to assess for differences between groups (CATC and GENOA) for continuous values
Chi-square test used to assess for differences between groups for categorical variables
GENOA Genetics of Opioid Addiction, CATC Canadian Addiction Treatment Centres, SD standard deviation, MMT methadone maintenance treatment, HIV human
immunodeficiency virus
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can vary from obvious psychotic disorders to any anxiety or
depressive disorder. Depending on the thoroughness of the
trial investigators and indeed the thoroughness of the clini-
cians administering the GENOA assessment tools (MINI,
BPI, MAP), differing rates of psychiatric problems will
be identified and could compromise the aims of our
study. Due to the serious limitations in reporting of
the definitions and measurements for many of the eli-
gibility criteria discussed across the literature, we cau-
tion the interpretation of the application of such
criteria using the GENOA study.
Provided we had reliable data on the medical and
demographic characteristics of opioid addiction patients,
we would be better equipped to demonstrate the clinical
guidelines are not appropriate for the US and UK
populations. Administrative data provided by Health
Maintenance Organizations in the US or the National
Health Service in the UK could serve as sources for
population-level data. However, the quality of this data
is questionable due to the high susceptibility for mis-
classification. A recent study evaluated the misclassifica-
tion of psychiatric disorders based on the comparison of
medical records and administrative data and found only
moderate agreement for any mental comorbidity [69].
We acknowledge the problems associated with opioid
dependence are impacted by the health, social, and judi-
cial systems, which can vary across countries. However,
to say the prevalence of psychiatric and physical comor-
bidity, as well as prescription of psychotropic medication
varies so much between countries, as well as types of ad-
diction populations such that it would render the larger
message of this study insignificant is improbable.
Conclusions
Findings from our analysis of the literature as well as ap-
plication of common eligibility criteria to a clinical sample
of patients with opioid use disorder demonstrate large
differences between the trial and clinical population of
opioid-dependent patients. Evaluation of the global con-
text and impact of these findings shows the concerning
state of addiction medicine, where we find the majority of
studies used to inform clinical practice are not generalizable
to the population seen in clinical practice. When more than
50 % of the addiction patient population suffers with co-
morbid psychiatric conditions, yet only a small fraction of
the evidence used to inform the current treatment strat-
egies for these patients is tested on patients with psychi-
atric conditions we are faced with a critical dilemma. Are
we providing the appropriate treatments? Are we com-
pleting our due diligence to this patient population? Are
we possibly putting our patients at risk? These questions
cannot be answered until the appropriate re-evaluation of
the evidence takes place using pragmatic trial designs and
implementation studies.
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